Previous clinical data (12 wk) generated with the partial agonist TAK-875 (fasiglifam) demonstrated improvement in HbA1c in T2D patients and recently, SCO-267, a full agonist compound was shown to improve glycemic control after single and multiple doses by stimulating the secretion of insulin, glucagon, and gut peptides in healthy adults, without increasing the risk of hypoglycemia (7, 8, 22). The gene discussed is GCG; the disease is type 2 diabetes mellitus.